Skip to main content
ZYME
NASDAQ Life Sciences

Zymeworks Raises 2026 Revenue Guidance to $337M-$351M Following $250M Jazz Milestone

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$30.81
Mkt Cap
$2.188B
52W Low
$16.003
52W High
$31.49
52W Position info
93% above low
Off High info
2.2% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

ZYME sits 93% above its 52-week low of $16.003.

Summary

Zymeworks posted Q3 revenue of $256.5M and net income of $173.7M, driven by the $250M Jazz milestone, and raised 2026 revenue guidance to $337M-$351M while stating it has no current plans for more equity issuance.


Key Events · Earnings and Guidance · ZYME

  • Guidance Raised Sharply for 2026

    Total revenue guidance rises to $337M-$351M from $278M-$292M, and Adjusted EBITDA to $176M-$190M from $114M-$128M, excluding future transactions and contingent on HSR clearance for the Roche collaboration.

  • Q3 Profit on $250M Jazz Milestone

    Total revenue reached $256.5M versus $27.6M a year earlier, including the $250.0M milestone earned after FDA approval of Ziihera in first-line HER2-positive GEA; net income was $173.7M, or $2.28 per diluted share.

  • No New Equity Planned

    To fund the Theravance acquisition and buybacks, Zymeworks accessed $600M of non-dilutive financing in 2026 at a weighted average cost below 10%, and it states no current plans for additional equity issuances.

  • Buybacks Total $279.8M Since 2024

    In the first nine months of 2026 the company repurchased 5,737,790 shares for $140.4M at an average of $24.48, and cumulatively since August 2024, 12,940,827 shares for $279.8M; about 69.0M shares were outstanding as of November 6, 2026.


Analysis · ZYME · Life Sciences

A $250M Jazz milestone tied to Ziihera's first-line GEA approval powered Zymeworks to a $173.7M third-quarter profit on $256.5M of revenue. The guidance raise matters more than the headline beat: full-year revenue is now $337M-$351M versus $278M-$292M, and Adjusted EBITDA $176M-$190M versus $114M-$128M, marking a step change in the earnings base rather than a one-off. Management also said it has no current plans for additional equity issuances, having funded the $929M Theravance deal with $600M of non-dilutive royalty-backed and senior notes. With the stock near its 52-week high of $31.49, the risk is that the milestone was already anticipated; the durable test is whether YUPELRI and royalty cash flows hold up once the one-time $250M drops out of the comparison.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ZYME was trading at $30.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $16.00 to $31.49. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ZYME - Latest Insights

ZYME
Nov 09, 2026, 4:10 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $30.81
Real-time Price: $31.00 info
Change: +$0.190 (+0.62%) info
Market Cap: $2.188B info
ZYME
Nov 09, 2026, 4:05 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $30.81
Real-time Price: $31.00 info
Change: +$0.190 (+0.62%) info
Market Cap: $2.188B info
ZYME
Oct 24, 2026, 2:30 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $28.55
Real-time Price: $31.00 info
Change: +$2.45 (+9%) info
Market Cap: $2.188B info
ZYME
Oct 23, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $28.99
Real-time Price: $31.00 info
Change: +$2.01 (+7%) info
Market Cap: $2.188B info
ZYME
Sep 28, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $26.52
Real-time Price: $31.00 info
Change: +$4.48 (+17%) info
Market Cap: $2.188B info